Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study.
about
Personalized pharmacotherapy in diabetes care using clinical pharmacology data of basal insulin analogues.Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml.Differential effects of adiposity on pharmacodynamics of basal insulins NPH, glargine, and detemir in type 2 diabetes mellitusMetabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetesA retrospective study comparing neutral protamine hagedorn insulin with glargine as basal therapy in prednisone-associated diabetes mellitus in hospitalized patientsDuration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus.Impact of patient and treatment characteristics on glycemic control and hypoglycemia in patients with type 2 diabetes initiated to insulin glargine or NPH: A post hoc, pooled, patient-level analysis of 6 randomized controlled trials.Metabolic control and risk of hypoglycaemia during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis.Current insulin analogues in the treatment of diabetes: emphasis on type 2 diabetes.Insulin detemir: a review of its use in the management of diabetes mellitus.A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review.Flexibly timed once-daily dosing with degludec: a new ultra-long-acting basal insulin.Comparing dosing of basal insulin analogues detemir and glargine: is it really unit-per-unit and dose-per-dose?Old and new basal insulin formulations: understanding pharmacodynamics is still relevant in clinical practice.Insulin glargine metabolite 21(A) -Gly-human insulin (M1) is the principal component circulating in the plasma of young children with type 1 diabetes: results from the PRESCHOOL study.Insulin analogues in type 1 diabetes mellitus: getting better all the time.Euglycaemic glucose clamp: what it can and cannot do, and how to do it.Glargine co-administration with intravenous insulin in pediatric diabetic ketoacidosis is safe and facilitates transition to a subcutaneous regimen.Pivotal role of timely basal insulin replacement after metformin failure in sustaining long-term blood glucose control at a target in type 2 diabetes.Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes.International Forum for the Advancement of Diabetes Research and Care, April 29-30, 2011, Athens, Greece.Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes.Impact of Insulin Detemir Administration Time on Hypoglycemia Rates in Hospitalized Patients.Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial.The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes.Comparison of the dose-response pharmacodynamic profiles of detemir and glargine in severely obese patients with type 2 diabetes: A single-blind, randomised cross-over trial
P2860
Q30809002-AED4717F-E415-4760-BE3B-33B542C39FBAQ34543063-7EC05D84-8672-4543-91E4-B60BBD32649EQ35563681-3ED9D078-1DBA-48CA-B14F-1408092D73C3Q36426750-E510ED85-CDE4-40E3-B39B-D685613C23A4Q36899667-C3B0C566-22E5-4B4E-95DC-77F1C625FED5Q37561045-87EA843A-C806-444F-B095-F6DED27D50B5Q37626675-12A3AD99-920C-4747-93BC-8F1FABB508DDQ37964744-66A254E0-53C7-4AC3-B148-EDCD47218061Q37972941-DC4173DD-1E37-4CEF-8073-F9D691072BE2Q38056540-F10C2C12-D8FE-4981-8EEF-F2E9E7DA931DQ38095682-B315DAB1-1BE7-4628-A264-755AEB774775Q38098217-96973A8B-6F66-4B14-B839-524CFEEF7F31Q38176344-64E3F0FD-4D21-47C4-AC67-B2B5925A129FQ38176677-8C00A0E0-704E-4146-AE79-AE59734947A6Q38426608-D59D17CA-26CE-4039-BBA5-393490712D5FQ38692387-79887B58-2A3C-4E5F-BA3F-74585FBFBE13Q38871135-5E3CBB1B-AA93-4846-9AC0-96B6A0B0C990Q38997245-76BE3D72-3678-40AA-8EDB-D1E820AFEAA5Q39987991-99098E47-AE92-4223-841F-693184CEBF63Q41825022-313FA6F7-883C-46F4-9FB7-0B02CEA027E0Q42730182-839D0115-D294-4DF5-BD77-1C396A7F5830Q45127422-90FE5468-FF47-4E3C-AA79-0C12034953F2Q50063849-453C5431-8121-46E6-A820-3890EB5C3328Q51290322-61090150-5CDC-4215-967A-12A189608465Q53449720-BBE65372-210C-4A26-817D-0C7E80C44150Q58775144-CCC170FB-94C9-46D9-A026-79AC548DAD36
P2860
Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Pharmacokinetics and pharmacod ...... a randomized cross-over study.
@en
Pharmacokinetics and pharmacod ...... a randomized cross-over study.
@nl
type
label
Pharmacokinetics and pharmacod ...... a randomized cross-over study.
@en
Pharmacokinetics and pharmacod ...... a randomized cross-over study.
@nl
prefLabel
Pharmacokinetics and pharmacod ...... a randomized cross-over study.
@en
Pharmacokinetics and pharmacod ...... a randomized cross-over study.
@nl
P2093
P2860
P356
P1433
P1476
Pharmacokinetics and pharmacod ...... a randomized cross-over study
@en
P2093
Anna Marinelli Andreoli
Francesca Porcellati
Geremia B Bolli
Paola Candeloro
Paola Lucidi
Patrizia Cioli
Raffaela Fede
Stefania Marzotti
P2860
P304
P356
10.2337/DC10-1911
P407
P577
2011-04-15T00:00:00Z